Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy in resectable esophageal squamous cell carcinoma
NCT06852456Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Dec 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Qilu Pharmaceutical. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06852456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852456.